Clinical trial

Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

NCT04211922

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Alkotinib Capsules Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-01-21

PhasePHASE2

Conditions

ALK-positive Non-small Cell Lung Cancerunresolved

Interventions

Alkotinib CapsulesDRUG

Sponsors & collaborators

Suzhou Zelgen Biopharmaceuticals Co.,Ltdlead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04211922 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.